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Abstract: Prevention of nausea and vomiting is the main goal of antiemetic treatment in cancer 
patients scheduled to receive chemotherapy. To prevent acute emesis, antiemetics should be 
administered just before chemotherapy and patients should be protected for up to 24 hours after 
chemotherapy initiation. The emetogenic potential of chemotherapeutic agents guides clinicians 
towards the most appropriate antiemetic prophylaxis. Current guidelines recommend the use of 5-HT3 
receptor antagonist (RA) either alone or in combination with dexamethasone and/or a neurokinin-1 
RA both in the acute and delayed phases. The second-generation 5-HT3RA palonosetron exhibits 
a longer half-life and a higher binding affinity than older antagonists. Palonosetron has been 
approved by the FDA for the prevention of chemotherapy-induced nausea and vomiting (CINV) 
in patients scheduled to receive either moderately (MEC) or highly emetogenic chemotherapy 
(HEC) and for the prevention of delayed CINV in patients receiving MEC. The present review 
will discuss the role of palonosetron in the prevention of acute CINV.
Keywords: antiemetics, chemotherapy, nausea, vomiting, serotonin-receptor antagonists, 
palonosetron
Introduction
Cancer treatments give rise to additional acute and chronic symptoms that may 
severely impair quality of life. Nausea and vomiting are among the most common and 
unpleasant side effects of chemotherapy.1 Despite advances in both cytotoxic agents 
and supportive care treatments patients undergoing chemotherapy may still suffer 
from nausea and vomiting.2
The most clinically relevant antiemetic drugs are serotonin (5-HT3) receptor 
antagonists (5-HT3 RA), neurokinin-1 receptor antagonists (NK-1RA), and corticoste-
roids.3 At present, several 5-HT3RAs are commercially available for the management 
of chemotherapy-induced nausea and vomiting (CINV). This drug class includes 
the first-generation agents (ie, granisetron, ondansetron, tropisetron and dolasetron), 
and the novel second-generation antagonist palonosetron. The present review will 
discuss the role of palonosetron in the prevention of acute CINV.
Phases of CINV
Traditionally, CINV has been classified as acute or delayed based its temporal onset 
following chemotherapy. Acute CINV occurs within the first 24 hours after chemo-
therapy initiation, while delayed emesis occurs between days 2 to 5 (24 to 120 hours 
postchemotherapy).4 It should be noted that the strongest predictor of delayed CINV is 
the occurrence of symptoms in the acute phase, but delayed emesis arises in the absence Cancer Management and Research 2009:2 90
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of acute symptoms in 18% to 24% of patients.5 Patients 
who are not sufficiently protected from emesis during the 
first chemotherapy cycle are also at high risk of developing 
anticipatory nausea and vomiting.6 Anticipatory CINV is 
observed in patients whose emetic episodes are triggered by 
taste, odor sight, thoughts, or anxiety that is secondary to a 
history of poor response to antiemetic agents or inadequate 
antiemetic prophylaxis in the previous course of chemo-
therapy.7 Therefore adequate protection against CINV, 
starting from the first cycle of chemotherapy, is paramount 
to successful control of subsequent cycle emesis.3
Risk factors for CiNv
The severity of CINV is influenced by two different risk 
factors, namely chemotherapy and individual patient char-
acteristics (Figure 1). Antiemetic prophylaxis is given in 
relation to the emetogenic potential of the chemotherapy 
regimen, which has an intrinsic propensity to cause CINV, 
the severity of which depends on the class and dose of drugs 
administered. Intravenously administered cytotoxic agents 
were initially assigned to five levels of emetogenicity.7 More 
recently, chemotherapeutic agents have been divided into four 
emetic risk categories according to the percentage of patients 
having emetic episodes when no prophylactic antiemetic 
protection is provided: high (90%), moderate (30% to 90%), 
low (10% to 30%), and minimal (10%).8,9 In addition to 
the emetogenicity of chemotherapy, several patient-related 
factors may increase the risk of  CINV. These factors include a 
young age, female gender, history of low or no alcohol intake, 
experience of emesis during pregnancy, impaired quality of 
life, and previous experience with chemotherapy.3,10
Physiopathology
Although multiple neurotransmitters are involved in 
emetic pathways, dopamine, 5-HT3, substance P, and their 
corresponding receptors play a key role in the onset of   
CINV.11 Receptors for these transmitters are found in high 
numbers in the dorsal vagal complex, area postrema, and 
gastrointestinal tract; drugs that interact with these neu-
rotransmitter systems have been shown to be effective thera-
peutics for CINV. Chemotherapy damages the gastrointestinal 
tract and activates abdominal vagal afferents. Under drug 
stimulus, the enterochromaffin cells of the gastrointestinal 
mucosa release 5-HT3, which binds its receptor on the vagal 
afferent neurons. The binding between 5-HT3 and its receptor 
stimulates two specific areas in the central nervous system 
both located in the medulla: the chemoreceptor trigger zone 
(CTZ) and the vomiting center (VC). The CTZ is activated via 
blood or cerebrospinal fluid and invokes the release of various 
neurotransmitters, which stimulate the VC. Once activated, 
the VC modulates the efferent transmission to the respiratory, 
vasomotor, and salivary centers as well as to the abdominal 
RISK FACTORS
CHEMOTHERAPY PATIENTS
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Figure 1 Risk factors influencing the severity of chemotherapy-induced nausea and vomiting.
aexamples of HeC agents: cisplatin 50 mg/m2, cyclophosphamide 1.5 g/m2, dacarbazine, carmustine.
bexamples of MeC agents: carboplatin, cyclophosphamide,doxorubicin, epirubicin, irinotecan, oxaliplatin.
cexamples of LeC agents: etoposide, cetuximab, paclitaxel, topotecan, trastuzumab, bortezomib.
dexamples of MieC agents: bevacizumab, bleomycin, vinblastine, vinorelbine.Cancer Management and Research 2009:2 91
Palonosetron for nausea and vomiting Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
muscles, diaphragm, and esophagus, resulting in emesis. 
The primary site of action of 5-HT3RA is at the abdominal 
vagal afferents.12 Cytotoxic agents and other toxins increase 
release of 5-HT3, which subsequently activates its receptors. 
5-HT3RA abolishes the signal to the receptors associated with 
vagal afferents. In contrast, NK-1RA acts at the dorsal vagal 
complex in the medulla, inhibiting gastric emptying. 5-HT3 
receptors are also expressed centrally in the area postrema 
and in the nucleus tractus solitarii; thus 5-HT3RA also acts 
centrally, in synergy with the NK-1RA, which acts in brain 
regions.13,14
Initial clinical results with first-generation 5-HT3RAs led 
to the belief that serotonin plays a pivotal role in mechanisms 
underlying acute emesis. Indeed, it was hypothesized that 
the acute protection from CINV was mediated largely 
through attenuation of peripheral 5-HT3 receptors on the 
vagal afferents. Antiemetic treatment for the acute CINV is 
ineffective without the use of 5-HT3RA.11,12
Antiemetic therapy
Different drug classes are available for the prevention of 
CINV, but the three most commonly used classes include 
5-HT3RAs, corticosteroids, and NK-1RAs.3 Other agents, such 
as antihistamines and anticholinergics, are used infrequently 
due to their lacking antiemetic properties in CINV.15 As a 
class, 5-HT3RAs have very favorable antiemetic properties 
and are not associated with dopamine-related side effects.12 
As a result, these antagonists have become the mainstay of 
current antiemetic therapy. In the early 1980s, vomiting and 
nausea were ranked as the two most feared side effects of 
chemotherapy.16 In the 1990s, after the introduction of the first-
generation 5-HT3RAs, nausea was scored the most feared side 
effect, whereas vomiting only ranked as number five.17,18
Aprepitant is the first commercially available NK-1RA, 
and its addition to a 5-HT3RA and dexamethasone is currently 
recommended to prevent delayed CINV in patients treated 
with highly emetogenic chemotherapy (HEC) or anthracycline 
and cyclophosphamide (AC)-based regimens.3 The drug has 
a good safety profile, but its inhibitory effect on the CYP3A4 
enzyme requires dose adjustment with other substrates of 
CYP3A4, including dexamethasone and warfarin.19 It is 
thought that corticosteroids such as dexamethasone and 
methylprednisolone suppress CINV by limiting peritumoral 
inflammation and prostaglandin production.20 Corticoste-
roids are the most frequently used drug to prevent delayed 
CINV, since multiple-day administration of a first-generation 
5-HT3RA to prevent delayed emesis is not recommended in 
current antiemetic guidelines.6,21,22
With repeated courses of chemotherapy, emesis becomes 
progressively more difficult to control, although adequate 
control in the first cycle of chemotherapy is more likely 
to be associated with control of acute CINV in subsequent 
cycles.20 Uncontrolled emesis associated with chemotherapy 
can lead to such a negative experience that patients may 
refuse potentially life-saving treatment for their malignancy. 
Moreover, CINV can result in dehydration, electrolyte 
imbalance, and malnutrition, which can also affect patient’s 
quality of life. Therefore, control of nausea and vomiting 
starting from the first chemotherapy cycle plays an integral 
role in the overall treatment success for the cancer patient.
Antiemetic guidelines
Prevention of acute and delayed CINV is the main goal of 
antiemetic therapy in cancer patients who are scheduled to 
receive emetogenic chemotherapy. Antiemetic guidelines 
have been released by several organizations including the 
Multinational Association of Supportive Care in Cancer 
(MASCC), the American Society of Clinical Oncology, and 
the National Comprehensive Cancer Network.9,21,22 MASCC 
guidelines, that are endorsed by nine international oncology 
groups, divide chemotherapeutic agents into four emetic 
risk groups, and provide treatment recommendations for 
each group. The goal in the prophylaxis of acute CINV is to 
avoid any experience of nausea and vomiting within 24 hours 
after chemotherapy initiation. In general, the international 
guidelines for the prevention of acute CINV have attempted 
to indicate a common antiemetic scheme that includes the 
use of 5-HT3RA in combination with dexamethasone, with 
or without NK-1RA.
In recent years, antiemetic recommendations have 
changed according to relevant information available from 
clinical experience as well as data from controlled trials. The 
implementation of guidelines is therefore ongoing as new 
clinical data and new antiemetic agents become available. 
The latest version of MASCC guidelines was published in 
2006, but Herrstedt has recently summarized recommenda-
tions from the updated version of the guidelines, which are 
also available at the MASCC website (www.mascc.org).6 
Current MASCC recommendations for the prevention of 
acute CINV following HEC and MEC are summarized in 
Table 1.
Acute CINV
Acute CINV occurs within 24 hours after chemotherapy 
initiation, and the highest risk of emesis is within the first 
4 hours of treatment. Cytotoxic agents such as cisplatin are Cancer Management and Research 2009:2 92
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associated with an intense acute phase of emesis occurring on 
day 1, followed by a less intense delayed phase. Other agents 
such as cyclophosphamide and carboplatin are associated 
with less intense acute phase, but a more persistent delayed 
phase.23 In case of multiple-drug chemotherapy regimens, 
the emetogenic potential of the most emetic drug should be 
taken into account in the selection of antiemetic treatment, but 
an increased emetic potential of the chemotherapy regimen 
as a whole should also be considered (eg, single agents 
anthracycline and cyclophosphamide have moderate emetic 
potential but the combination exhibits high emetic potential). 
Patient-related risk factors should also be taken into account 
when assessing the risk of acute CINV. For patients under-
going multiple-day chemotherapy, it is difficult to establish 
whether the onset of the emesis is acute or delayed, due to 
the overlap of both events. At each day of chemotherapy, 
a new stimulus of acute CINV appears and, in this setting, 
the tailoring of antiemetic treatment is more complex.23 In 
multiple-day chemotherapy regimens, antiemetic prophylaxis 
should achieve long-lasting inhibition of the 5-HT3 receptors 
due to the persistence of the emetic stimulus throughout the 
entire chemotherapy cycle.
Prophylaxis of acute CiNv
To prevent acute emesis, antiemetic treatment should be 
administered just before chemotherapy and patients should 
be protected for up to 24 hours following chemotherapy 
initiation. Current guidelines recommend the use of a 
5-HT3RA as part of the antiemetic prophylaxis for acute 
CINV after HEC or moderately emetogenic chemotherapy 
(MEC).6,21,22 Selection of the appropriate antiemetic treatment 
to be administered prior to chemotherapy is influenced by 
the following emetic risk groups:
High emetic risk group: patients should be given a 
combination of 5-HT3RA, dexamethasone, and NK-1RA. 
Patients who are scheduled to receive an AC-based chemo-
therapy should be given the same antiemetic prophylaxis.
Moderate emetic risk group: patients should be given a 
5-HT3RA in combination with dexamethasone.
Low emetic risk group: patients should receive a low 
dose of dexamethasone.
The antiemetic guidelines do not differentiate among 
the 5-HT3RAs, suggesting that they have similar efficacy. 
A meta-analysis of randomized trials was conducted to 
compare efficacy of the first-generation 5-HT3RAs for the 
prevention of acute CINV in patients receiving cisplatin- and 
noncisplatin-based chemotherapy.24 The authors concluded 
that antiemetic efficacy of these antagonists was comparable 
in the acute phase. The second-generation 5-HT3RA 
palonosetron was only briefly mentioned in that review, 
as very few comparative trials were available for the analysis 
at that time.
Palonosetron
Palonosetron is a new second-generation 5-HT3RA that 
showed better protection than older antagonists against CINV 
following MEC in the FDA registration trials.25,26 Palonosetron 
is approved by Health Authorities for the prevention of 
acute and delayed CINV at a dose of 0.25 mg intravenously 
administered prior to chemotherapy. It also should be noted 
that palonosetron is the only 5-HT3RA that received the FDA 
approval for the prevention of delayed CINV following MEC. 
A recently reported randomized phase III trial conducted 
in Japan demonstrated that palonosetron in combination 
with dexamethasone is significantly more efficacious than 
is the combination of granisetron and dexamethasone in 
the prevention of delayed CINV following HEC.27
Pharmacological profile
In comparison with older 5-HT3RAs which exhibit half-
lives in the range of 4–9 hours, palonosetron has a longer 
mean elimination half-life of approximately 40 hours.28 
Palonosetron also has a higher binding affinity for the 5-HT3 
receptor that is at least 30-fold higher than the first-generation 
setrons.
Mechanism of action
The nature of the interaction of palonosetron with the 5-HT3 
receptor has recently been investigated.29 The antagonism of 
palonosetron is due to allosteric inhibition of the receptor. 
In contrast, ondansetron and granisetron engage in competitive 
Table 1 MASCC guidelines for the prevention of  acute 
chemotherapy-induced nausea and vomiting following HeC 
and MeC6
Emetic risk category 
 
Recommended antiemetic 
regimen on day 1 (administered 
prior to chemotherapy)
HeC 5-HT3 receptor antagonist 
+ Dexamethasone 
+ NK-1 receptor antagonist
MeC 
(anthracycline and 
cyclophosphamide-based)
5-HT3 receptor antagonist
+ Dexamethasone
+ NK-1 receptor antagonist
MeC 5-HT3 receptor antagonist 
+ Dexamethasone
Abbreviations: MASCC, Multinational  Association of Supportive Care in Cancer; 
HeC, highly emetogenic chemotherapy; MeC, moderately emetogenic chemotherapy.Cancer Management and Research 2009:2 93
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antagonism of the 5-HT3 receptor. Structural studies have also 
indicated that palonosetron exhibits positive cooperativity, in 
contrast to ondansetron and granisetron which exhibit simple 
bimolecular interactions. Differential reduction in binding at 
cell surfaces is consistent with palonosetron triggering either 
5-HT3 receptor internalization or inactivation.
Safety profile
A single dose of palonosetron has been found to have a 
tolerability profile comparable to other drug class members; 
headache, constipation, and dizziness were the most 
commonly reported adverse events. In March 2008 and 
February 2009 the FDA and EMEA, respectively, updated 
the prescribing information of palonosetron with additional 
cardiac safety results from a randomized, double-blind, 
placebo- and moxifloxacin-controlled dose-response study on 
230 healthy volunteers, specifically focusing on changes in 
the QT interval.30,31 Single doses of intravenous palonosetron 
ranging from 0.25 to 2.25 mg were assessed. There was no 
dose-related electrocardiograph effects or any evidence of 
QTc interval prolongation.32
Registration trials
The efficacy and safety of a fixed, single intravenous dose of 
palonosetron in preventing CINV have been assessed in five 
phase I, one phase II, and three phase III trials.33
Two randomized, double-blind, phase III, noninferiority 
trials comparing palonosetron with ondansetron or dolasetron 
in patients who received MEC demonstrated the efficacy of 
palonosetron compared with first-generation 5-HT3RAs. The 
primary endpoint of both studies was the proportion of patients 
achieving a complete response (CR; no emesis and no rescue 
medication) during the acute phase following the first cycle 
of chemotherapy. Gralla et al compared single intravenous 
doses of palonosetron (0.25 mg and 0.75 mg) with a single 
intravenous dose of ondansetron (32 mg), while Eisenberg 
et al compared palonosetron with a single intravenous dose 
of dolasetron (100 mg).25,26 Results of both trials showed 
that palonosetron is noninferior to, or more efficacious than 
are older antagonists in the prevention of acute and delayed 
CINV after MEC. A third trial with an identical noninferiority 
design using HEC compared single intravenous doses of 
palonosetron with a single dose of ondansetron immediately 
prior to chemotherapy.34 In this study, palonosetron resulted 
noninferior to ondansetron in the prevention of CINV during 
the acute, delayed, and overall phases.
In the registration trials, both palonosetron doses 
(0.25 mg and 0.75 mg) were noninferior to ondansetron or 
dolasetron for the prevention of acute CINV after MEC. 
Therefore, the lowest fully effective palonosetron dose was 
approved by the FDA.
Palonosetron for the prevention  
of acute CiNv
A number of clinical trials have demonstrated that 
palonosetron provides a high protection against the acute 
CINV after MEC and HEC regimens (Table 2). A pooled 
analysis of the two registration trials using MEC showed that 
palonosetron induces a statistically significant improvement 
in the CR rate during the acute phase compared with pooled 
data from patients who received ondansetron or dolasetron 
(72% versus 61%, respectively).36 In addition, within the 
combined cohort of patients pretreated with palonosetron, 
significantly higher proportion of emesis-free patients was 
observed than those receiving ondansetron or dolasetron 
during the acute phase after MEC (79% versus 65%).37,38
Analysis of pooled data from registration trials using 
MEC was performed to assess the hypothesis that the 
ability of palonosetron to prevent delayed CINV could be 
simply a carryover effect from better control of symptoms 
in the acute phase.38 Among emesis-free patients in the 
acute phase, a significantly greater proportion receiving 
palonosetron experienced no delayed CINV compared with 
those who received ondansetron or dolasetron (80% versus 
69%, respectively). A similar trend was noted for those 
patients who had acute CINV. These findings suggest that the 
improved ability of palonosetron to prevent delayed CINV 
is unlikely to be simply a carryover effect and highlight the 
differentiating features of palonosetron in exerting a direct 
effect in the delayed phase, a unique characteristic among 
the agents from the same drug class.
In a noninferiority phase III trial published in 2006, 
single agent palonosetron was demonstrated to be at least 
as effective as ondansetron in preventing acute CINV from 
HEC; the CR rates were slightly higher with palonosetron 
than ondansetron during the delayed and overall phases.34 
It is worth to note that 67% of the patients in that study 
also received prophylactic dexamethasone 20 mg only 
prior to chemotherapy. In this subgroup of patients, there 
was a not statistically significant improvement in the 
acute CR rate in favour of the palonosetron group over 
the ondansetron group (65% versus 56%). It also should 
be noted that patients pretreated with palonosetron who 
also received dexamethasone had significantly higher CR 
rates than those receiving ondansetron plus dexamethasone, 
during both the delayed (42% versus 29%) and overall Cancer Management and Research 2009:2 94
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(41% versus 25%) phases after chemotherapy. Therefore, 
the investigators stated that palonosetron administered 
with dexamethasone, as per current antiemetic guidelines, 
was significantly more effective than ondansetron plus 
dexamethasone in preventing CINV during the overall 
5-day period after HEC.
A recently reported multicenter, double-blind, phase III 
trial conducted in Japan evaluated the efficacy and safety 
of intravenous single dose of palonosetron (0.75 mg) versus 
intravenous single dose of granisetron (40 µg/kg) for the 
prevention of CINV, both of which were administered with 
dexamethasone in patients who were scheduled to receive 
HEC or AC-based chemotherapy.27 Primary endpoints 
were the proportion of patients with a CR during the acute 
phase (noninferiority comparison with granisetron) and 
the proportion of patients with a CR during the delayed phase 
(superiority comparison with granisetron). A total of 418 of 
555 patients (75%) in the palonosetron group achieved CR 
during the acute phase compared with 410 of 559 patients 
(73%) in the granisetron group (mean difference 2.9% 
[95% CI, –2.70 to 7.27]).
In contrast to the older 5-HT3RAs, palonosetron has been 
shown to effectively control nausea, which remains one of the 
major unmet needs in management of emesis. Palonosetron 
achieved higher proportion of nausea-free patients compared 
with those who received ondansetron in the acute phase after 
MEC administration (60% versus 57%).25 Effective control 
of nausea starting from the first day of chemotherapy may 
contribute to maintain a good quality of life and adequate 
caloric intake, which in turn is related to the ability of patient 
to continue with the anticancer treatment.39
A number of postmarketing trials have been published 
that confirm efficacy of palonosetron for the prevention of 
CINV either alone or in combination with dexamethasone, 
Table 2 Prevention of acute chemotherapy-induced nausea and vomiting: results of clinical trials with palonosetron
Reference 
 
No. of  
patients 
Emetic risk  
category 
Antiemetic 
regimen 
on Day 1
CR (%) 
 
Emesis-free 
patients (%) 
Randomized studies
Gralla 200325 189 MeC Palo 0.25 mg 
aDex 20 mg
81 85
eisenberg 200326 189 MeCb Palo 0.25 mg 
aDex 20 mg
64 72
Aapro 200634 223 HeC Palo 0.25 mg 
aDex 20 mg
59 68
Yu 200935 104 HeC Palo 0.25 mg 83 NA
Saito 200927 239 MeC (AC-based) Palo 0.75 mg 
Dex 16 mg
69 NA
Saito 200927 316 HeC Palo 0.75 mg 
Dex 16 mg
80 NA
Nonrandomized studies
Grote 200643 58 MeCc Palo 0.25 mg 
Dex 12 mg 
Apr 125 mg
88 93
Navari 200747 32 MeC Palo 0.25 mg 
Dex 8 mg 
Olanzapine 10 mg
97 97
Giuliani 200840 85 MeC Palo 0.25 mg 
Dex 8 mg
99 99
Grunberg 200845 41 MeC Palo 0.25 mg 
Dex 20 mg 
Apr 285 mg
76 100
Lorusso 200939  35  HeC  Palo 0.25 mg 
Dex 20 mg
86  NA 
aCorticosteroid given at the discretion of the investigator; bthe cohort includes 120 patients receiving AC-based chemotherapy; cthe cohort includes 24 patients receiving 
AC-based chemotherapy.
Abbreviations: CR, complete response; MeC, moderately emetogenic chemotherapy; HeC, highly emetogenic chemotherapy;   AC, anthracycline and cyclophosphamide; Palo, 
palonosetron, Dex, dexamethasone;   Apr, aprepitant; NA, not available.Cancer Management and Research 2009:2 95
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with or without other drug classes, in the clinical settings of 
MEC, HEC and multiple-day chemotherapy.35,39–45,47
Palonosetron in patients receiving 
oxaliplatin-based chemotherapy
An open-label, multicenter, phase II study evaluated the 
safety and efficacy of intravenous single dose of palonosetron 
in combination with dexamethasone (8 mg intravenously) on 
day 1 to prevent CINV in patients with colorectal cancer who 
were scheduled to receive oxaliplatin-based chemotherapy 
(Folfox-4 regimen) as an adjuvant.40 The vast majority of 
patients achieved CR and did not experience vomiting during 
the acute phase after chemotherapy initiation.
Palonosetron in patients receiving 
multiple-day chemotherapy
Einhorn et al evaluated 41 patients undergoing 5-day 
cisplatin-based chemotherapy for testicular cancer who 
received intravenous palonosetron (0.25 mg once daily) 
30 min before chemotherapy on days 1, 3, and 5 plus intra-
venous dexamethasone (20 mg) before chemotherapy on 
days 1 and 2, and 8 mg bid orally on days 6 and 7 and 4 mg 
bid on day 8.41 Fifty-one percent of patients experienced no 
emesis throughout days 1 to 5, while the majority (83%) 
were free from emesis throughout days 6 to 9. In addition, 
patients experienced no moderate to severe nausea, and did 
not require rescue medication.
Musso et al administered a single dose of palonose-
tron just before chemotherapy and dexamethasone (8 mg) 
throughout the entire period of multiple-day chemotherapy.42 
Forty-six patients suffering from hematologic malignancies 
were enrolled; 80% of them did not experience vomiting 
during chemotherapy administration.
Palonosetron in combination 
with aprepitant
An open-label, multicenter, phase II trial assessed the efficacy 
of intravenous single dose of palonosetron, along with 
dexamethasone (12 mg on day 1, 8 mg on days 2 and 3), 
and 3 daily oral doses of aprepitant (125 mg on day 1, 80 mg 
on days 2 and 3) in patients receiving MEC.43 AC-based 
chemotherapy was the most commonly administered regimen 
(41%). CR occurred in 88% of patients during the acute phase, 
and 93% experienced no emesis during the acute phase.
Herrington et al conducted a pilot, single-institution, 
double-blind, placebo-controlled trial that evaluated three 
different antiemetic regimens.44 All patients received 
intravenous single dose of palonosetron on day 1 and 
dexamethasone on days 1 to 4 after HEC administration. 
Arm A received aprepitant 125 mg orally on day 1 followed 
by 80 mg on days 2 to 3; arm B received aprepitant on day 1 
and placebo on days 2 to 3; and arm C received placebo on 
days 1 to 3. Primary endpoint was the proportion of patients 
who experienced acute and delayed emesis within each 
group. Seventy-five patients were included in the analysis. 
In either arm including aprepitant, approximately 100% of 
patients were free from emesis during the acute phase, while 
approximately 70% of patients achieved CR.
Recently, Grunberg et al evaluated the efficacy of a 
single-day three-drug regimen of palonosetron, aprepitant 
(285 mg), and dexamethasone (20 mg) before chemotherapy 
initiation in 41 patients receiving MEC.45 CR was seen in 
76% of patients during the acute phase, and no emesis was 
reported for 100% of patients in the same period.
Palonosetron in combination 
with olanzapine
Olanzapine is an atypical antipsychotic drug that interacts with 
the dopamine, serotonin, muscarinic cholinergic, adrenergic, 
and histamine receptors. It has been shown to be an effective 
agent in controlling delayed CINV.46 The most recent trial con-
ducted by Navari et al demonstrated high complete protection 
against both acute and delayed nausea.47 Forty chemotherapy-
naïve patients received on the day 1 of chemotherapy an 
antiemetic regimen consisting of dexamethasone (8 mg for 
MEC or 20 mg for HEC), and palonosetron (0.25 mg) before 
chemotherapy. Patients also began olanzapine, 10 mg orally, 
on day 1 and continued 10 mg daily for days 2 to 4 after 
chemotherapy administration. The vast majority of patients 
(97%) experienced CR during the acute phase.
Conclusions
Prevention of CINV improves the quality of life in cancer 
patients, as reflected in an increased ability to complete 
household tasks, maintain daily functioning, and complete 
chemotherapeutic treatment.48 For optimal control of CINV, 
the patient should not experience nausea and vomiting within 
24 hour following chemotherapy initiation, because control 
of acute CINV is a positive predictor for successful control 
of delayed emesis. To prevent acute emesis, antiemetic 
treatment should be administered just before chemotherapy 
and patients should be protected for up to 24 hours after 
chemotherapy initiation. The emetogenic potential of chemo-
therapeutic agents guides clinicians towards the most appro-
priate antiemetic prophylaxis. Current guidelines recommend Cancer Management and Research 2009:2 96
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the use of 5-HT3RA, dexamethasone, and NK-1RA to prevent 
CINV after administration of HEC and AC-based regimens. 
In patients receiving MEC, guidelines recommend a combi-
nation of 5-HT3RA and dexamethasone before chemotherapy 
initiation.
Palonosetron is a unique 5-HT3RA as it exhibits a higher 
binding affinity, extended half-life and a different mechanism 
of action compared to the first-generation agents. The antago-
nism of palonosetron is due to allosteric inhibition of the 
receptor.29 Since 5-HT3 activation of the receptor is involved 
in emesis, an allosteric antagonist that is harder to displace 
would be able to control CINV for longer periods of time. 
Palonosetron has been shown to be more effective than older 
5-HT3RAs for the prevention of delayed CINV after HEC 
and MEC administration.25–27 However, a pooled analysis of 
two phase III trials with an identical noninferiority design 
using MEC demonstrated that palonosetron also induces a 
statistically significant improvement in the CR rates during 
the acute phase compared with pooled data from patients 
who received older 5-HT3RAs.36 The ability of palonosetron 
to achieve better control of acute CINV may contribute to 
successful control of delayed and subsequent cycle emesis.
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